Pneumococcal vaccination in children with acute lymphocytic leukemia

Related Experiment Video

Updated: Aug 18, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

S Feldman, W Malone, R Wilbur

    Medical and Pediatric Oncology
    |January 1, 1985
    PubMed

    Insights

    Children with acute lymphoblastic leukemia (ALL) showed a poor response to pneumococcal vaccination. Antibody levels remained suboptimal six months post-vaccination, indicating a need for improved immunization strategies in this vulnerable population.

    Area of Science:

    • Pediatric Oncology
    • Immunology
    • Vaccinology

    Background:

    • Children with acute lymphoblastic leukemia (ALL) often have compromised immune systems.
    • Standard vaccination protocols may be less effective in immunocompromised pediatric patients.
    • Pneumococcal infections pose a significant risk to children undergoing cancer treatment.

    Purpose of the Study:

    • To evaluate the immunogenicity of the 14-valent pneumococcal vaccine in children with ALL in complete clinical remission (CCR).
    • To assess antibody responses at various time points following immunization in pediatric ALL patients.
    • To determine the proportion of patients achieving protective antibody levels against pneumococcal serotypes.

    Main Methods:

    • Sixty-three children with ALL in CCR were immunized with a 14-valent pneumococcal vaccine.
    • Vaccination occurred at different time points: post-remission induction, post-therapy completion, or at diagnosis.
    • Antibody levels were measured at 6-month follow-up to assess vaccine response.

    Main Results:

    • The overall response to pneumococcal vaccination was suboptimal across the study cohort.
    • By 6-month follow-up, only two out of 14 serotypes elicited protective antibody levels (≥300 ng/ml) in over half of the patients.
    • Vaccination timing did not appear to significantly alter the suboptimal immune response.

    Conclusions:

    • The 14-valent pneumococcal vaccine demonstrates limited efficacy in inducing protective antibody levels in children with ALL in CCR.
    • Current immunization strategies may require optimization to enhance vaccine responsiveness in this immunocompromised pediatric population.
    • Further research is needed to explore alternative or adjunctive immunotherapies for pneumococcal disease prevention in pediatric cancer patients.

    More Related Videos

    Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

    Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

    Published on: February 23, 2014

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

    Published on: October 17, 2025

    Related Concept Videos

    Acute Pharyngitis01:30

    Acute Pharyngitis

    Introduction
    Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
    Classification
    Acute pharyngitis can be categorized based on its underlying cause:
    Pneumonia I: Introduction01:30

    Pneumonia I: Introduction

    Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
    Risk Factors
    Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
    Pneumonia III: Complications and Assessment01:30

    Pneumonia III: Complications and Assessment

    Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    Pneumonia V: Nursing management and Prevention01:30

    Pneumonia V: Nursing management and Prevention

    Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
    The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
    Enhance airway patency
    Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
    Pneumonia I: Introduction01:29

    Pneumonia I: Introduction

    Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...